Tag Archives: HAE

Barrington Remains a Hold on Haemonetics (HAE)

In a report released today, Michael Petusky from Barrington maintained a Hold rating on Haemonetics (HAE – Research Report). The company’s shares closed last Tuesday at $86.26. According to TipRanks.com, Petusky is a 4-star analyst with an average return of

Analysts Offer Insights on Healthcare Companies: Haemonetics (NYSE: HAE), Teva Pharmaceutical Industries (NYSE: TEVA) and Arcturus Therapeutics (NASDAQ: ARCT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Haemonetics (HAE – Research Report), Teva Pharmaceutical Industries (TEVA – Research Report) and Arcturus Therapeutics (ARCT – Research Report) with bullish sentiments.

Analysts Are Bullish on These Healthcare Stocks: Haemonetics (HAE), uniQure (QURE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Haemonetics (HAE – Research Report) and uniQure (QURE – Research Report) with bullish sentiments. Haemonetics (HAE) Needham analyst Michael Matson assigned a

Needham Reaffirms Their Buy Rating on Haemonetics (HAE)

In a report released today, Michael Matson from Needham reiterated a Buy rating on Haemonetics (HAE – Research Report), with a price target of $132.00. The company’s shares closed last Tuesday at $108.38. According to TipRanks.com, Matson is a 5-star

Morgan Stanley Sticks to Their Buy Rating for Haemonetics (HAE)

Morgan Stanley analyst David Lewis maintained a Buy rating on Haemonetics (HAE – Research Report) today and set a price target of $138.00. The company’s shares closed last Monday at $102.99. According to TipRanks.com, Lewis is a 4-star analyst with

Haemonetics (HAE) Received its Third Buy in a Row

After Needham and Raymond James gave Haemonetics (NYSE: HAE) a Buy rating last month, the company received another Buy, this time from Barrington. Analyst Michael Petusky maintained a Buy rating on Haemonetics today and set a price target of $141.00.